Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cemiplimab vs platinum chemotherapy in PD-L1 ≥50% advanced NSCLC (China)
CTR20191453Phase 3Completed
- Sponsor
- Sanofi
- Start
- Jul 2019
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of cemiplimab in non-small cell lung cancer (NSCLC), sponsored by Sanofi. Started Jul 2019; status: completed.
02
Drugs
cemiplimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20191453.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20191453.